Literature DB >> 8878067

KATP channel openers reverse immune complex-induced airways hyperreactivity independently of smooth muscle relaxation.

K H Buchheit1, A Hofmann.   

Abstract

Many openers of ATP-dependent potassium channels (KATP channel openers) cause bronchorelaxation, whereas only a few of them have been claimed to reverse airways hyperreactivity. We investigated whether the antihyperreactive effect is a general feature of KATP channel openers and whether this property is linked to their ability to relax airways smooth muscle. For this purpose, the potency of the four KATP channel openers, bimakalim, rilmakalim, levcromakalim and SDZ PCO 400 ((-)-(3S,4R)-3,4-dihydro-3-hydroxy-2,2-dimethyl-4-(3-oxo-cyclopent -1 -enyloxy)-2H-1-benzopyran-6-carbonitrile), to inhibit bombesin- or histamine-induced bronchoconstriction and to reverse immune complex-induced airways hyperreactivity to histamine in guinea pigs, was compared to salbutamol, following intratracheal administration to minimize pharmacokinetic differences. Total lung resistance (RL) was determined in anaesthetized, ventilated guinea pigs. Bronchoconstriction, measured as increase in RL, was elicited in normoreactive animals by i.v. infusion of bombesin (100 ng/kg/min) or by i.v. injection of histamine (1.8-10 micrograms/kg). Airways hyper-reactivity was induced by acute i.v. administration of preformed immune complexes. I.v. bolus injections of histamine were used to define the sensitivity of the airways prior to and after the exposure to immune complex. Levcromakalim (ED50 = 150 micrograms/kg), bimakalim (ED50 = 4 micrograms/kg), rilmakalim (ED50 = 40 micrograms/kg) and SDZ PCO 400 (ED50 = 280 micrograms/kg) reverse bombesin-induced bronchoconstriction with lower potency than salbutamol (ED50 = 1 microgram/kg). The four KATP channel openers and salbutamol also reversed immune complex-induced airways hyperreactivity to histamine with ED50 values which were markedly lower than those for reversal of bombesin-induced bronchoconstriction; the rank order of potency was rilmakalim (ED50 = 0.2 microgram/kg) > bimakalim (ED50 = 0.5 microgram/kg) > SDZ PCO 400 (ED50 = 3.2 micrograms/kg) > levcromakalim (ED50 = 22 micrograms/kg). Salbutamol (ED50 = 0.008 microgram/kg) was the most potent compound in this test. Bimakalim, levcromakalim and SDZ PCO 400 did not inhibit histamine-induced bronchoconstriction in normoreactive guinea pigs at doses which completely reversed immune complex-induced airways hyperreactivity to histamine. For rilmakalim and salbutamol, 60-130 times higher doses were needed for protection against histamine-induced bronchoconstriction in normoreactive guinea pigs than for reversal of airways hyperreactivity. There was a poor correlation between the ED50 values for inhibition of histamine- or bombesin-induced bronchoconstriction in normoreactive guinea pigs and the reversal of immune complex-induced airways hyperreactivity. It is thus concluded that the ability of KATP channel openers to reverse immune complex-induced airways hyperreactivity is independent of their ability to reverse or prevent bronchoconstriction and thus from their ability relax airway smooth muscle.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8878067     DOI: 10.1007/bf00171068

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  15 in total

1.  Tolerance to the nonbronchodilator effects of inhaled beta 2-agonists in asthma.

Authors:  B J O'Connor; S L Aikman; P J Barnes
Journal:  N Engl J Med       Date:  1992-10-22       Impact factor: 91.245

2.  Structure-activity studies of potassium channel opening in pinacidil-type cyanoguanidines, nitroethenediamines, thioureas, and ureas.

Authors:  P W Manley; U Quast
Journal:  J Med Chem       Date:  1992-06-12       Impact factor: 7.446

3.  Bombesin-induced bronchoconstriction in the guinea pig: mode of action.

Authors:  M G Belvisi; C D Stretton; P J Barnes
Journal:  J Pharmacol Exp Ther       Date:  1991-07-01       Impact factor: 4.030

Review 4.  Potassium channel openers: airway pharmacology and clinical possibilities in asthma.

Authors:  D Raeburn; J A Karlsson
Journal:  Prog Drug Res       Date:  1991

Review 5.  Potassium channel openers and asthma.

Authors:  J Morley
Journal:  Clin Rev Allergy       Date:  1994

6.  Airway pharmacology of the potassium channel opener, HOE 234, in guinea pigs: in vitro and in vivo studies.

Authors:  H C Englert; K Wirth; D Gehring; U Fürst; U Albus; W Scholz; B Rosenkranz; B A Schölkens
Journal:  Eur J Pharmacol       Date:  1992-01-07       Impact factor: 4.432

7.  Long-term effects of a long-acting beta 2-adrenoceptor agonist, salmeterol, on airway hyperresponsiveness in patients with mild asthma.

Authors:  D Cheung; M C Timmers; A H Zwinderman; E H Bel; J H Dijkman; P J Sterk
Journal:  N Engl J Med       Date:  1992-10-22       Impact factor: 91.245

8.  Synthesis and antihypertensive activity of 4-(1,2-dihydro-2-oxo-1-pyridyl)-2H-1-benzopyrans and related compounds, new potassium channel activators.

Authors:  R Bergmann; R Gericke
Journal:  J Med Chem       Date:  1990-02       Impact factor: 7.446

9.  Effects of pinacidil on guinea-pig airway smooth muscle contracted by asthma mediators.

Authors:  J E Nielsen-Kudsk; S Mellemkjaer; C Siggaard; C B Nielsen
Journal:  Eur J Pharmacol       Date:  1988-11-22       Impact factor: 4.432

10.  NIP-121 and cromakalim, potassium channel openers, preferentially suppress prostanoid-induced contraction of the guinea-pig isolated trachea.

Authors:  K Shikada; A Yamamoto; S Tanaka
Journal:  Eur J Pharmacol       Date:  1991-12-10       Impact factor: 4.432

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.